Daiichi Life offered A$11.80 a share for the rest of Challenger, and the stock jumped to its highest since 2018

Challenger shares rose 16.65% to A$11.49 by mid-morning on Monday, October 19, 2026, their highest level since October 2018, after a unit of Japan's Daiichi Life offered A$11.80 a share for the part of the Australian retirement-income company it does not already own. The non-binding proposal from TAL Daiichi Life Australia values all of Challenger at about A$7.94 billion (US$5.53 billion), and Challenger's board said it is considering it.

Challenger announced the proposal to the Australian Securities Exchange at 8:01 a.m. Sydney time on Monday, 21:01 UTC on Sunday, and told shareholders they need take no action. The A$11.80 price is 19.8% above Friday's close of A$9.85 and 17.7% above the one-month volume-weighted average price of A$10.03.

The terms

The offer depends on due diligence, an agreed scheme of arrangement, regulatory approvals and the support of Challenger's board, and Challenger said there is no certainty it will lead to a binding offer. At A$11.49, the stock traded A$0.31 below the offer, a gap of about 2.7%. The gap reflects the chance that the deal is delayed, cut or abandoned, and the time until any payment.

Why Daiichi Life wants Challenger

The bidder, TAL Daiichi Life Australia, is Daiichi Life's Australian life insurance unit. It became a Challenger shareholder in April 2025, when it bought a 15.1% stake from Japan's MS&AD Insurance Group, and it has added to that holding since. Challenger sells annuities, which turn retirement savings into a regular income, and runs a funds management business. Reuters noted that Japanese insurers are buying abroad because a shrinking population limits their growth at home.

Challenger also released its first-quarter update for fiscal 2027 on Monday. Total sales rose 52% to A$4.4 billion from a year earlier, and funds under management rose 5% over the quarter to A$31.9 billion.